502 related articles for article (PubMed ID: 28362071)
1. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients.
Villanueva-Millán MJ; Pérez-Matute P; Recio-Fernández E; Lezana Rosales JM; Oteo JA
J Int AIDS Soc; 2017 Mar; 20(1):21526. PubMed ID: 28362071
[TBL] [Abstract][Full Text] [Related]
2. Integrase Inhibitors Partially Restore Bacterial Translocation, Inflammation and Gut Permeability Induced by HIV Infection: Impact on Gut Microbiota.
Villoslada-Blanco P; Pérez-Matute P; Íñiguez M; Recio-Fernández E; Blanco-Navarrete P; Metola L; Ibarra V; Alba J; de Toro M; Oteo JA
Infect Dis Ther; 2022 Aug; 11(4):1541-1557. PubMed ID: 35618952
[TBL] [Abstract][Full Text] [Related]
3. Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy.
Annavajhala MK; Khan SD; Sullivan SB; Shah J; Pass L; Kister K; Kunen H; Chiang V; Monnot GC; Ricupero CL; Mazur RA; Gordon P; de Jong A; Wadhwa S; Yin MT; Demmer RT; Uhlemann AC
mSphere; 2020 Feb; 5(1):. PubMed ID: 32024712
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.
Torres HA; Rallapalli V; Saxena A; Granwehr BP; Viola GM; Ariza-Heredia E; Adachi JA; Chemaly RF; Marfatia R; Jiang Y; Mahale P; Kyvernitakis A; Fanale MA; Mulanovich V
Clin Microbiol Infect; 2014 Oct; 20(10):O672-9. PubMed ID: 24529214
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota diversity predicts immune status in HIV-1 infection.
Nowak P; Troseid M; Avershina E; Barqasho B; Neogi U; Holm K; Hov JR; Noyan K; Vesterbacka J; Svärd J; Rudi K; Sönnerborg A
AIDS; 2015 Nov; 29(18):2409-18. PubMed ID: 26355675
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes.
Ancona G; Merlini E; Tincati C; Barassi A; Calcagno A; Augello M; Bono V; Bai F; Cannizzo ES; d'Arminio Monforte A; Marchetti G
Front Immunol; 2021; 12():639291. PubMed ID: 33717191
[No Abstract] [Full Text] [Related]
7. Distinct gut microbiota profile in antiretroviral therapy-treated perinatally HIV-infected patients associated with cardiac and inflammatory biomarkers.
Sessa L; Reddel S; Manno E; Quagliariello A; Cotugno N; Del Chierico F; Amodio D; Capponi C; Leone F; Bernardi S; Rossi P; Putignani L; Palma P
AIDS; 2019 May; 33(6):1001-1011. PubMed ID: 30946154
[TBL] [Abstract][Full Text] [Related]
8. Altered gut microbiome composition in HIV infection: causes, effects and potential intervention.
Bandera A; De Benedetto I; Bozzi G; Gori A
Curr Opin HIV AIDS; 2018 Jan; 13(1):73-80. PubMed ID: 29045252
[TBL] [Abstract][Full Text] [Related]
9. Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine.
Ray S; Narayanan A; Giske CG; Neogi U; Sönnerborg A; Nowak P
ACS Infect Dis; 2021 May; 7(5):1104-1115. PubMed ID: 33346662
[TBL] [Abstract][Full Text] [Related]
10. The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.
Quiros-Roldan E; Castelli F; Bonito A; Vezzoli M; Calza S; Biasiotto G; Zanella I;
Cytokine; 2020 Feb; 126():154884. PubMed ID: 31670006
[TBL] [Abstract][Full Text] [Related]
11. Changes in intestinal microbiota in HIV-1-infected subjects following cART initiation: influence of CD4+ T cell count.
Ji Y; Zhang F; Zhang R; Shen Y; Liu L; Wang J; Yang J; Tang Q; Xun J; Qi T; Wang Z; Song W; Tang Y; Chen J; Lu H
Emerg Microbes Infect; 2018 Jun; 7(1):113. PubMed ID: 29934497
[TBL] [Abstract][Full Text] [Related]
12. Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection.
Mak G; Zaunders JJ; Bailey M; Seddiki N; Rogers G; Leong L; Phan TG; Kelleher AD; Koelsch KK; Boyd MA; Danta M
Front Immunol; 2021; 12():688886. PubMed ID: 34135912
[TBL] [Abstract][Full Text] [Related]
13. Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation.
Ishizaka A; Koga M; Mizutani T; Parbie PK; Prawisuda D; Yusa N; Sedohara A; Kikuchi T; Ikeuchi K; Adachi E; Koibuchi T; Furukawa Y; Tojo A; Imoto S; Suzuki Y; Tsutsumi T; Kiyono H; Matano T; Yotsuyanagi H
Microbiol Spectr; 2021 Sep; 9(1):e0070821. PubMed ID: 34378948
[TBL] [Abstract][Full Text] [Related]
14. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
[TBL] [Abstract][Full Text] [Related]
15. Beyond the effects of HIV infection and integrase inhibitors-based therapies on oral bacteriome.
Villoslada-Blanco P; Pérez-Matute P; Recio-Fernández E; Íñiguez M; Blanco-Navarrete P; Metola L; Ibarra V; Alba J; de Toro M; Oteo JA
Sci Rep; 2023 Aug; 13(1):14327. PubMed ID: 37653055
[TBL] [Abstract][Full Text] [Related]
16. Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance.
Munjoma PT; Chandiwana P; Wyss J; Mazhandu AJ; Jordi SBU; Gutsire R; Katsidzira L; Yilmaz B; Misselwitz B; Duri K
Front Immunol; 2023; 14():1280262. PubMed ID: 38045684
[TBL] [Abstract][Full Text] [Related]
17. Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients.
Imahashi M; Ode H; Kobayashi A; Nemoto M; Matsuda M; Hashiba C; Hamano A; Nakata Y; Mori M; Seko K; Nakahata M; Kogure A; Tanaka Y; Sugiura W; Yokomaku Y; Iwatani Y
Sci Rep; 2021 Jan; 11(1):960. PubMed ID: 33441754
[TBL] [Abstract][Full Text] [Related]
18. Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens.
Pinto-Cardoso S; Lozupone C; Briceño O; Alva-Hernández S; Téllez N; Adriana A; Murakami-Ogasawara A; Reyes-Terán G
Sci Rep; 2017 Mar; 7():43741. PubMed ID: 28262770
[TBL] [Abstract][Full Text] [Related]
19. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.
Hileman CO; Funderburg NT
Curr HIV/AIDS Rep; 2017 Jun; 14(3):93-100. PubMed ID: 28434169
[TBL] [Abstract][Full Text] [Related]
20. Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.
Russo E; Nannini G; Sterrantino G; Kiros ST; Di Pilato V; Coppi M; Baldi S; Niccolai E; Ricci F; Ramazzotti M; Pallecchi M; Lagi F; Rossolini GM; Bartoloni A; Bartolucci G; Amedei A
World J Gastroenterol; 2022 Feb; 28(6):635-652. PubMed ID: 35317423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
